Taro Pharma

Notes

• Controlled (78.5% ownership) by Sun Pharma — an India-based drug company; attempted several takeovers at low prices in years’ past
• US generics company (mostly dermatology products) with huge net cash position
• 2018 sales fell off from generic competition and patent losses

‣

2020-2021 hit particularly hard from COVID and generic competition

‣

EV/FCF is outrageously cheap... depending on the normalization of recent legal settlements, could be 1-2x FCF — cheap stocks can (and will) get cheaper!

Resources

‣

Link to Taro model

TARO Model

Last modified by Value Don't Lie 2 months ago

docs.google.com